Shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) have been given an average rating of “Buy” by the ten brokerages that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target […]
Equities analysts expect Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) to report earnings per share of ($1.45) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Turning Point Therapeutics’ earnings, with estimates ranging from ($1.72) to ($0.67). Turning Point Therapeutics posted earnings per share of ($0.73) during the […]
PALM BEACH, Fla., April 14, 2022 /PRNewswire/ FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell
/PRNewswire/ FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient s T cells which is a type of immune system.
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.